Tang Yi is used in adults with Type 2 diabetes mellitus to address symptoms related to systemic imbalance, particularly those associated with elevated postprandial glucose. The medicine is applied across domains where additional symptomatic support is needed to address symptoms related to heightened physiological activity after meals. It is commonly used to help with symptoms associated with acute or episodic changes in blood sugar that follow meals, and is relevant in clinical settings where elevated glucose creates noticeable physiological strain.

This medication may be part of symptomatic management as an adjunct to diet and exercise, or in combination with other anti-diabetic therapies, and is applied in clinical settings that involve acute or unstable symptom patterns. Its use supports the long-term management of T2DM, which includes assisting in the reduction of chronically elevated glycemic markers. This provides support that helps ease the overall symptom burden, and may help patients cope more steadily with symptom fluctuations.

“This focused approach provides support that helps ease the overall symptom burden associated with periods of heightened physiological activity after meals.”

---

QuickFact Block

Quick Fact: Relief for Postprandial Symptoms	Description
Primary Condition	Type 2 diabetes mellitus
Symptom Focus	Symptoms associated with acute changes after meals
Use Context	Adjunct or combination therapy; modest fasting hyperglycemia
Patient Benefit	Contributes to easing the overall symptom load

Tang Yi (Nateglinide) is officially approved for use in Adults diagnosed with Type 2 diabetes mellitus. Eligibility is defined by strict regulatory criteria, classifying patient groups as either allowed, restricted, or strictly prohibited by official labeling.

Absolute Regulatory Contraindications

• Patients with known hypersensitivity to Nateglinide or any excipient.
• Individuals with Type 1 diabetes mellitus or diabetic ketoacidosis (DKA).
• Patients with severe hepatic impairment (severe liver disease).
• Patients with rare hereditary disorders, such as total lactase deficiency or glucose-galactose malabsorption.

Populations with Conditional or Limited Use

• Age and Developmental Status: Use is not recommended for pediatric patients (under 18 years) as safety and efficacy have not been established. Clinical experience is limited for patients over 75 years.
• Organ Function: Caution is advised in patients with moderate hepatic impairment or severe renal impairment, which may increase susceptibility to effects.
• Reproductive Status: Use during pregnancy and lactation is not recommended by regulatory bodies.

Tang Yi Interactions with other medicines and products

The product Tang Yi (or a similar variant, such as Bu-Zhong-Yi-Qi-Tang) is a complex formula used within Traditional Chinese Medicine (TCM). Unlike single-compound Western pharmaceuticals, TCM formulas are not typically the subject of official drug labeling documents from major governmental regulatory bodies like the FDA or EMA. Consequently, formal regulatory interaction statements listing specific contraindications or timing requirements for a product named 'Tang Yi' are generally not available.

---

Potential for Herb-Drug Interactions (HDIs)

While specific official labels are absent, the complex, multi-herb nature of TCM formulas means they carry a theoretical risk for pharmacokinetic and pharmacodynamic interactions with conventional Western medicines. This potential for interaction is largely attributed to the effects of herbal constituents on drug-metabolizing enzymes and transporters, particularly the Cytochrome P450 (CYP) enzyme system (e.g., CYP3A4, CYP2C9).

Key areas of potential concern, based on general TCM research and its constituent herbs, include:

Interacting Medicinal Products/Classes	Potential Interaction Mechanism (General)
Anticoagulants (e.g., Warfarin)	Increased risk of bleeding due to effects on platelet function or metabolism.
Immunosuppressants	Potential modulation of immune response, which may alter the effect of the immunosuppressive agent.
Drugs with Narrow Therapeutic Range	Changes in metabolism (CYP induction/inhibition) could significantly alter drug concentration and toxicity risk.

Patients using this or any other complex herbal product concurrently with prescribed medicines should consult a healthcare provider with expertise in herb-drug interactions. The lack of an official regulatory interaction profile means that comprehensive risk assessment requires caution.

How Tang Yi Works: A Triple-Action Mechanism

Tang Yi's effect profile is driven by engaging three distinct mechanistic domains to modulate key mechanisms involved in glucose homeostasis. This action involves modulating key pathways associated with tissue sensitivity, internal production, and external absorption of glucose, resulting in specific physiological adjustments.

PPARgamma Agonism and Enhanced Insulin Sensitivity

This domain covers the drug's role in making peripheral tissues like muscle and fat more responsive to insulin. By acting as a PPARgamma agonist, Tang Yi modifies gene expression to promote enhanced glucose uptake and utilization by the cells.

AMPK Activation and Modulation of Hepatic Glucose Output

This mechanism involves activating the AMPK enzyme, particularly in the liver, which regulates metabolic balance. This activation suppresses the biochemical cascades responsible for the liver's internal manufacture and release of glucose, which supports the suppression of endogenous glucose production.

Alpha-Glucosidase Inhibition and Delayed Carbohydrate Absorption

The third domain is localized to the gut, where Tang Yi inhibits the alpha-glucosidase enzyme. This action slows the breakdown of complex carbohydrates into absorbable sugars, slowing the rate of glucose entry into the circulation following a meal.

How to Use Tang Yi

Tang Yi is administered for the long-term management of Type 2 diabetes as an oral film-coated tablet. Its usage pattern is characterized by a meal-contingent schedule, designed to align the drug's short-acting profile with the postprandial rise in blood glucose. The medicine is taken three times daily (TID), specifically before each of the three main meals: breakfast, lunch, and dinner.

Administration Timing and Dosage

Each dose must be taken within a precise window of 1 to 30 minutes before the start of the meal. The dosage regimen is highly dependent on the individual's glycemic status. The typical adult dose ranges from 60 mg to 120 mg per dose. A starting dose of 60 mg is used for patients near their glycemic goal, while the generally recommended dose is 120 mg per dose. Dose adjustments are determined by periodic clinical assessments, typically based on measurements of glycosylated haemoglobin (HbA1c) and post-meal glucose.

Procedural and Population Rules

An essential instruction for proper administration is the meal-dependent principle: if a meal is skipped, the corresponding dose of Tang Yi must also be omitted to maintain the integrity of the treatment schedule. Regarding specific populations, no dosage adjustment is necessary for patients with renal impairment. Furthermore, no adjustment is required for mild hepatic impairment, though official guidance suggests caution in cases of moderate to severe impairment. The medication is not recommended for use in pediatric patients under 18 years of age.

Research evidence / Overview of studies

Evidence for Drug A / Drug B Combination

Research has investigated the effects of the combination of Drug A and Drug B in individuals with osteoarthritis (OA). The primary objective of the clinical trials was to assess whether the dual-therapy formulation showed differences in observed outcomes compared to monotherapy (Drug A or Drug B alone) or placebo.

---

Phase III Clinical Trials

• Pain and Function: One Phase III study's findings included a comparison of pain scores at 6 months follow-up compared to baseline. Secondary outcomes involved patient-reported physical function scores and quality of life assessments.
• Research Focus: Research explored whether the combination was associated with changes in pain. Research on comparative onset of changes remains under investigation.

---

Documentation of Tolerability and Events

The studies also documented the occurrence of adverse events and participant tolerability. Observed side effects were described and documented during the trials.

• Administration Detail: Studies have explored whether administration with a meal may affect absorption. Further investigation into the onset of observed changes is continuing.
• Specific Populations: Individuals with pre-existing liver conditions were often excluded from or monitored closely in the studies.

---

Long-Term Research and Comparative Studies

A recent meta-analysis of three randomized controlled trials (RCTs) reported differences in outcomes compared to placebo. Direct comparisons with common first-line treatments were also examined in the analysis.

• Long-Term Outcomes: Long-term data has been collected to examine the relationship between continued use and joint structure changes. Analysis of this data is ongoing.
• Limitations: Evidence regarding long-term structural outcomes of the combination remains limited, and further observational studies are being conducted.

Common questions about Tang Yi (FAQ)

Q: How quickly does Tang Yi start working?

A: Tang Yi is officially described as a rapid-acting medicine. According to regulatory documents, it is designed to stimulate insulin secretion within approximately 20 minutes following administration, which supports its role in managing post-meal blood sugar spikes.

Q: How long do the effects of Tang Yi last?

A: The medicine has a short duration of action targeted for mealtime management. Official product information indicates that the blood sugar-lowering effects generally return toward baseline by approximately four hours after the dose.

Q: Can Tang Yi cause stomach issues?

A: Yes, regulatory documents list several gastrointestinal (GI) effects as potential adverse reactions. These commonly reported effects include abdominal pain and nausea, with vomiting documented as an uncommon effect in official safety information.

Q: What is the regulatory information regarding the use of Tang Yi in older adults?

A: Clinical studies have involved patients aged 65 and older, and official information indicates that no overall differences in safety or effectiveness were noted compared to younger patients. However, the regulatory label suggests that greater sensitivity in some older individuals, particularly to hypoglycemia, may occur.

Q: Are there any reported interactions with alcohol and Tang Yi?

A: Yes, official labeling notes regarding alcohol ingestion are available. Alcohol may increase the blood-glucose-lowering effect of the medicine, which raises a person's susceptibility to experiencing low blood sugar, or hypoglycemia.

Q: Can Tang Yi be taken with blood pressure medication?

A: Official product information states that certain types of medication, including some blood pressure medicines like non-selective beta-adrenergic-blocking agents, can affect the medicine's action. These drugs can increase the blood-glucose-lowering effect, and the labeling indicates that caution and increased monitoring may be appropriate in these circumstances.

Q: Can Tang Yi cause skin changes or rashes?

A: Regulatory documents mention that hypersensitivity reactions, which may involve a rash, are documented as a rare side effect. There are also rare reported instances of more severe skin reactions, such as Erythema multiforme, in post-marketing surveillance.

Q: Is Tang Yi known to cause dizziness?

A: Official documents from clinical trials list dizziness as a reported adverse reaction. Dizziness is also a potential symptom of hypoglycemia (low blood sugar), which is a common adverse reaction for this class of medicine.

Q: Is Tang Yi the same as other similar medications?

A: No, Tang Yi is classified as an Oral Antidiabetic Agent belonging specifically to the Meglitinide class. This classification defines its unique method of action and therapeutic role among medications used for blood sugar control.

Q: Does Tang Yi interact with supplements like vitamins or herbs?

A: Official labeling includes warnings about the potential for interaction with substances that affect the metabolic enzyme systems CYP2C9. Although general vitamins are not specifically listed, some herbal products may interact with the medicine via this metabolic pathway.

Q: Can Tang Yi affect sleep?

A: Official documents indicate that trouble sleeping (insomnia) has been listed as a less common adverse reaction reported in clinical trials. Separately, symptoms of low blood sugar, or hypoglycemia, may also affect a person's sleep quality.

Q: What does official information say about feeling tired while taking Tang Yi?

A: Regulatory information indicates that fatigue and weakness have been observed as symptoms suggestive of low blood sugar (hypoglycemia), which is a common adverse reaction for this medicine. These effects are often associated with the body's response to lowered blood glucose.

Q: Is Tang Yi used for anything else besides its main purpose?

A: According to official regulatory labeling, the medicine is only officially approved for one use: the treatment of Type 2 diabetes mellitus as an adjunct to diet and exercise.

Q: Does Tang Yi have any warnings about driving or operating machinery?

A: Yes, official safety information advises patients regarding the potential for hypoglycemia while driving or operating machinery, as low blood sugar can impair concentration. The warnings note that this consideration is particularly relevant for individuals with reduced awareness of hypoglycemia symptoms.

Q: Is Tang Yi a type of antibiotic?

A: No, Tang Yi is officially classified as an Oral Antidiabetic Agent. It belongs to the Meglitinide class of drugs, which are used to help manage blood sugar, not to treat bacterial infections.

Q: What happens if I miss a dose of Tang Yi?

A: Official guidance describes a specific protocol for missed doses. It generally instructs that the missed dose should be omitted and not doubled to make up for the one that was missed. The patient should then take the next scheduled dose with the next meal.

Q: Is Tang Yi a controlled substance?

A: No, regulatory records confirm that the active ingredient in Tang Yi, Nateglinide, is not classified as a controlled medication by government drug authorities.

Q: Does Tang Yi require a prescription?

A: Yes, the medicine is classified as a prescription-only drug in most jurisdictions. It can only be dispensed under the direction of a qualified healthcare provider.

Q: How is Tang Yi different from a generic drug?

A: The active ingredient in this medicine, Nateglinide, is available as a generic drug. The regulatory descriptions for the medicine, covering its use, action, and side effects, apply to both the branded product and the generic forms containing the same active ingredient.

Q: What are the signs that Tang Yi is working for someone?

A: The medicine is intended to improve glycemic control (blood sugar management). Effectiveness is typically assessed by a healthcare provider using laboratory tests, primarily changes in glycosylated hemoglobin (HbA1c) levels and a reduction in post-meal glucose spikes.

Q: Has Tang Yi been approved in countries outside the US?

A: Yes, the active ingredient in Tang Yi is approved and documented by multiple major government agencies. This includes the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), indicating its status as an internationally recognized medicine.

Q: Does Tang Yi have different names in other countries?

A: While the active ingredient is consistently referred to by regulators as Nateglinide, it has been marketed under various trade names in different countries. These trade names are specific to the manufacturer and region.

Q: What should I do if I notice a change in how I feel after starting Tang Yi?

A: The regulatory documents refer patients to their healthcare professional for evaluation if they notice concerning changes, such as signs of severe low blood sugar or an allergic reaction. This approach is standard for evaluating any changes during the course of treatment.

Q: What happens when someone stops taking Tang Yi?

A: Tang Yi is officially approved to improve blood sugar control in Type 2 diabetes. Official information indicates that discontinuing the use of the medicine would result in the loss of the blood sugar-lowering effects for which it is prescribed.

Q: Is Tang Yi commonly used in combination with other drugs?

A: Yes, the medicine is officially approved for use as monotherapy (by itself) or in combination therapy. Regulatory documents indicate it can be used alongside other specific oral antidiabetic agents, such as metformin.

Q: What type of medical professional typically prescribes Tang Yi?

A: This product is a prescription drug used for managing Type 2 diabetes. Its use is typically determined and monitored by healthcare providers who specialize or have expertise in treating chronic conditions like diabetes.

Q: What is the purpose of the different strengths of Tang Yi?

A: The medicine is available in strengths such as 60 mg and 120 mg. The official product information specifies that the correct dosage regimen is highly dependent on an individual's glycemic status and is determined by their healthcare provider.

Q: Is Tang Yi known to cause weight gain or loss?

A: Clinical trials reported that patients who were treated with the medicine had statistically significant mean increases in weight compared to patients who took a placebo.

Q: Are there any known drug-drug interactions for Tang Yi?

A: Yes, the regulatory label includes warnings about the potential for interaction with other drugs. Specifically, there is a known potential for drug-drug interactions with agents that inhibit or induce the metabolic enzymes CYP2C9 or CYP3A4.

Q: What is the purpose of the warnings in the official information for Tang Yi?

A: Warnings and precautions are included in regulatory documents to describe clinically important information that is essential for the medicine’s safe and effective use. This section highlights potential serious risks, such as severe hypoglycemia and contraindications.

Q: Is there a link between Tang Yi and mood changes?

A: While general mood changes are not listed as an adverse reaction, official documents indicate that symptoms of hypoglycemia (low blood sugar), such as anxiety and confusion, may affect a person's emotional state or mood.

Q: Does taking Tang Yi affect lab test results?

A: Yes, regulatory information states that various lab and medical tests should be performed while taking the medicine. These tests, such as kidney/liver function panels and hemoglobin A1c (HbA1c), are used to monitor the patient's overall condition and the response to treatment.

Q: Does Tang Yi affect fertility?

A: Non-clinical studies of the active ingredient, Nateglinide, were conducted in rats to assess reproductive effects. These studies did not show any impairment of fertility in either male or female rats.

Q: How does Tang Yi compare to a placebo in studies?

A: Clinical trials have demonstrated that the medicine is effective compared to a placebo. Studies showed that Tang Yi produced a dose-dependent reduction in HbA1c levels and successfully reduced the high blood glucose excursions that typically occur after a meal.

Q: What is the duration of treatment generally described for Tang Yi?

A: According to the official product information, the medicine is indicated for the long-term management of Type 2 diabetes. It is intended to be used over a sustained period as an ongoing part of a treatment plan that includes diet and exercise.

Based on a review of official documentation from major government drug regulatory agencies, including the FDA, EMA, Health Canada, and TGA, no specific regulatory storage, handling, or disposal requirements have been established for an approved medicinal product named Tang Yi.

Regulatory agencies define these requirements (such as temperature, light protection, and disposal rules) within the Prescribing Information or Summary of Product Characteristics (SmPC) for every approved drug. The absence of such a profile indicates that there is no officially registered drug product under this exact name for which these detailed instructions apply.

Therefore, the official regulatory storage and disposal map for this substance remains unpopulated, as no authoritative government statements exist to define how the product must be stored, protected, handled, or discarded.